Caligan Partners
Latest statistics and disclosures from Caligan Partners's latest quarterly 13F-HR filing:
- Top 5 stock holdings are LQDA, ABVX, MLYS, AGIO, EXEL, and represent 73.42% of Caligan Partners's stock portfolio.
- Added to shares of these 10 stocks: AGIO (+$42M), ADMA (+$39M), MLYS (+$29M), RVMD (+$20M), XENE (+$18M), AVTX (+$11M), INBX (+$8.0M), TYRA (+$7.1M), EOLS, VRCA.
- Started 5 new stock positions in XENE, AVTX, ADMA, INBX, VRCA.
- Reduced shares in these 7 stocks: VRNA (-$136M), MRUS (-$41M), ABVX (-$19M), Y Mabs Therapeutics (-$11M), RZLT (-$6.9M), , Verrica Pharmaceuticals.
- Sold out of its positions in BCRX, RZLT, VRNA, Verrica Pharmaceuticals, Y Mabs Therapeutics.
- Caligan Partners was a net seller of stock by $-43M.
- Caligan Partners has $764M in assets under management (AUM), dropping by 46.78%.
- Central Index Key (CIK): 0001727492
Tip: Access up to 7 years of quarterly data
Positions held by Caligan Partners consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Caligan Partners
Caligan Partners holds 17 positions in its portfolio as reported in the September 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Liquidia Corporation Com New (LQDA) | 24.2 | $185M | 8.1M | 22.74 |
|
|
| Abivax Sa Sponsored Ads (ABVX) | 16.1 | $123M | -13% | 1.5M | 84.90 |
|
| Mineralys Therapeutics (MLYS) | 13.8 | $105M | +37% | 2.8M | 37.92 |
|
| Agios Pharmaceuticals (AGIO) | 11.1 | $85M | +96% | 2.1M | 40.14 |
|
| Exelixis (EXEL) | 8.3 | $63M | 1.5M | 41.30 |
|
|
| Revolution Medicines (RVMD) | 6.5 | $50M | +67% | 1.1M | 46.70 |
|
| Adma Biologics (ADMA) | 5.1 | $39M | NEW | 2.6M | 14.66 |
|
| Evolus (EOLS) | 3.3 | $25M | +23% | 4.1M | 6.14 |
|
| Merus N V (MRUS) | 2.7 | $20M | -66% | 217k | 94.15 |
|
| Xenon Pharmaceuticals (XENE) | 2.3 | $18M | NEW | 445k | 40.15 |
|
| Anika Therapeutics (ANIK) | 1.8 | $14M | 1.4M | 9.40 |
|
|
| Avalo Therapeutics Com New (AVTX) | 1.4 | $11M | NEW | 833k | 12.71 |
|
| Tyra Biosciences (TYRA) | 1.3 | $9.7M | +266% | 697k | 13.99 |
|
| Inhibrx Biosciences (INBX) | 1.0 | $8.0M | NEW | 236k | 33.68 |
|
| Verrica Pharmaceuticals Com Shs (VRCA) | 0.5 | $4.0M | NEW | 924k | 4.31 |
|
| Sellas Life Sciences Group I Com New Call Option (SLS) | 0.5 | $3.7M | 2.3M | 1.61 |
|
|
| Aura Biosciences (AURA) | 0.2 | $1.4M | +13% | 227k | 6.18 |
|
Past Filings by Caligan Partners
SEC 13F filings are viewable for Caligan Partners going back to 2022
- Caligan Partners 2025 Q3 filed Nov. 14, 2025
- Caligan Partners 2025 Q2 filed Aug. 14, 2025
- Caligan Partners 2025 Q1 filed May 15, 2025
- Caligan Partners 2024 Q4 filed Feb. 14, 2025
- Caligan Partners 2024 Q3 filed Nov. 14, 2024
- Caligan Partners 2024 Q2 filed Aug. 14, 2024
- Caligan Partners 2024 Q1 filed May 13, 2024
- Caligan Partners 2023 Q4 filed Feb. 14, 2024
- Caligan Partners 2023 Q3 filed Nov. 14, 2023
- Caligan Partners 2023 Q2 filed Aug. 14, 2023
- Caligan Partners 2023 Q1 filed May 15, 2023
- Caligan Partners 2022 Q4 restated filed May 15, 2023
- Caligan Partners 2022 Q4 filed Feb. 15, 2023